Core Viewpoint - Medline Inc. has announced the pricing of its upsized initial public offering (IPO) of 216,034,482 shares of Class A common stock at a price of $29.00 per share, with trading expected to begin on December 17, 2025, under the symbol "MDLN" [1]. Group 1: IPO Details - The underwriters have been granted a 30-day option to purchase an additional 32,405,172 shares of Class A common stock [1]. - Medline plans to use the proceeds from the issuance of 179,000,000 shares to repay outstanding indebtedness under its senior secured term loan facilities, with the remainder allocated for general corporate purposes and offering expenses [1]. - The offering is expected to close on December 18, 2025, subject to customary closing conditions [1]. Group 2: Underwriters and Managers - Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities, and J.P. Morgan are acting as global coordinators and lead bookrunning managers for the offering [2]. - A number of other financial institutions are involved as bookrunning managers and co-managers for the proposed offering [2]. Group 3: Company Overview - Medline is the largest provider of medical-surgical products and supply chain solutions, serving all points of care [5]. - The company has a broad product portfolio, resilient supply chain, and leading clinical solutions aimed at improving healthcare providers' clinical, financial, and operational outcomes [5]. - Medline is headquartered in Northfield, Illinois, employs over 43,000 people worldwide, and operates in more than 100 countries [5].
Medline Announces Pricing of Upsized Initial Public Offering